share_log

BrainsWay Announces The Publication Of Feasibility Clinical Data Evaluating The Analgesic Effects Of Deep Transcranial Magnetic Stimulation In Patients With Peripheral Neuropathic Pain. The Results Were Published In The Neuromodulation Journal, In A...

ブレインズウェイは、末梢神経障害性疼痛を訴える患者における深部経頭蓋磁気刺激の鎮痛効果を評価した実現可能性臨床データの発表を行いました。結果は、神経調節学ジャーナルに掲載されました...

Benzinga ·  11/20 08:26

BrainsWay Announces The Publication Of Feasibility Clinical Data Evaluating The Analgesic Effects Of Deep Transcranial Magnetic Stimulation In Patients With Peripheral Neuropathic Pain. The Results Were Published In The Neuromodulation Journal, In A Peer-Reviewed Article Entitled, "H-Coil Repetitive Transcranial Magnetic Stimulation Relieves Pain And Symptoms Of Anxiety And Depression In Patients With Chronic Peripheral Neuropathic Pain: A Randomized Sham-Controlled Crossover Study."

BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the publication of positive feasibility clinical data evaluating the analgesic effects of deep transcranial magnetic stimulation (Deep TMS) in patients with peripheral neuropathic pain. The results were published in the Neuromodulation journal, in a peer-reviewed article entitled, "H-Coil Repetitive Transcranial Magnetic Stimulation Relieves Pain and Symptoms of Anxiety and Depression in Patients with Chronic Peripheral Neuropathic Pain: A Randomized Sham-Controlled Crossover Study."

The double-blind, randomized crossover trial included seventeen (17) patients with chronic neuropathic pain. Participants were assigned to either an active Deep TMS or sham treatment arm for a five-day period, followed by a nine-week washout, before crossing over to the other arm. The study's primary outcome measure was a comparison between the patterns of the active and sham groups' self-reported changes in pain levels from baseline. Secondary outcomes included changes in pain ratings at specific time points in the two arms, as well as changes in comorbid symptoms experienced by the patients, including, for example, anxiety and depression.

Results showed that Active deep-TMS therapy significantly reduced "usual pain intensity" in patients with chronic peripheral neuropathic pain compared to sham treatment and improved symptoms of anxiety and depression in the same patient population.

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする